ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Dermatology"

  • Abstract Number: 0285 • ACR Convergence 2025

    Delayed-Onset Myopathy in Dermatomyositis: A Retrospective Cohort Study

    Connor Buechler1, Nawang Singhe2, Lindsey Wanberg2, Cody Rasner2, Joseph McGrath2, Karen Baker-James2, Rebecca Freese2 and David Pearson3, 1University of Minnesota, Mendota Heights, MN, 2University of Minnesota, Minneapolis, MN, 3Department of Dermatology, University of Minnesota, Minneapolis, MN

    Background/Purpose: Amyopathic dermatomyositis (ADM) is a subset of DM in which cutaneous findings occur without muscle disease for >6 months after diagnosis. However, there is…
  • Abstract Number: 1912 • ACR Convergence 2025

    Cutaneous manifestations of vasculitis: A cross-sectional analysis from an international cohort

    Robert Micheletti1, William Song1, Brian Chu2, Lynne Allen-Taylor3, Joel Gelfand3, Peter Grayson4, Cristina Ponte5, Joanna Robson6, Ravi Suppiah7, Raashid Luqmani8, Richard Watts9 and Peter Merkel10, 1Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 2Brown University Health, Providence, RI, 3University of Pennsylvania, Philadelphia, 4National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Chevy Chase, MD, 5Unidade Local de Saúde de Santa Maria, Lisbon, Portugal, 6University of the West of England Bristol, Bristol, United Kingdom, 7Health New Zealand - Te Toka Tumai, Auckland, New Zealand, 8University of Oxford, Oxford, United Kingdom, 9University of East Anglia, Norwich, United Kingdom, 10University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Vasculitis is a group of rare, multisystem diseases which may involve the skin. Characterization of the frequency, type, and significance of cutaneous manifestations in…
  • Abstract Number: 0278 • ACR Convergence 2025

    Classic and Clinically Amyopathic Dermatomyositis: Autoantibody Positivity

    Xiwei Yang1, Shae Chambers2, Aretha On1, Hammad Ali2, Touraj Khosravi3, Lais Lopes Almeida Gomes2, Rui Feng4 and Victoria Werth5, 1Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 2University of Pennsylvania, Philadelphia, PA, 3Department of Dermatology, Perelman Shool of Medicine, University of Pennsylvania, Philadelphia, PA, 4Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania, Philadelphia, PA, 5University of Pennsylvania, Wynnewood, PA

    Background/Purpose: Dermatomyositis (DM) is an idiopathic inflammatory myopathy subclassified as classic (CDM) and clinically amyopathic (CADM). It can involve myositis-associated (MAA) and myositis-specific (MSA) autoantibodies.…
  • Abstract Number: 1898 • ACR Convergence 2025

    Assessing Representation in a Nation-Wide Psoriasis Registry: A Single-Institution Comparison

    Evelyn Fagan1, Joseph McGrath1, Calla Sullivan1, Mackenzie Kilton1, Kaeli Samson2, Kaleb Michaud3 and Sarah Lonowski1, 1University of Nebraska Medical Center Department of Dermatology, Omaha, NE, 2University of Nebraska Medical Center Department of Biostatistics, Omaha, NE, 3University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Ensuring that data registries include a representative sample is crucial for obtaining findings that can be generalized to the larger population. This comparative observational…
  • Abstract Number: 0277 • ACR Convergence 2025

    A Phase 1, Randomized Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Single and Multiple Ascending Doses and Food Effects of BGB-45035, a chimeric degradation activating compound (CDAC), in Healthy Participants

    Vaibhav Mundra1, Cunjing Yu2, Roland Morley1, Yuan Yuan3, Yifan Qin3, Jingjing Schneider1, Shengnan Chen3, Zhenyuan Zhou3 and Zhen Yao2, 1BeOne Medicines USA, Inc., San Carlos, CA, 2BeOne Medicines (Beijing) Co, Ltd., Beijing, China (People's Republic), 3BeOne Medicines (Shanghai) Co, Ltd., Shanghai, China (People's Republic)

    Background/Purpose: Interleukin 1 receptor associated kinase 4 (IRAK4) degradation may modulate toll-like receptor signaling and alleviate symptoms in rheumatoid arthritis and atopic dermatitis.1,2 BGB-45035, an…
  • Abstract Number: 1464 • ACR Convergence 2025

    Incidence of Major Adverse Cardiovascular Events (MACE) in Psoriasis, Psoriatic Arthritis and Axial Spondyloarthritis Patients With and Without Cardiovascular Risk Factors Treated With Secukinumab: Five-Year Safety Data from the Real-World SERENA Study

    Uta Kiltz1, Petros Sfikakis2, Andreas Bounas3, Nicola Gullick4, Eric LESPESSAILLES5, Jan Brandt-Juergens6, Rasho Rashkov7, Cynthia Vizcaya8, Andreas Clemens8, Lara Gómez9, Kim Hoyt10, Weibin Bao11 and Karl Gaffney12, 1Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, 2NKUA - SCHOOL OF MEDICINE, Athens, Greece, 3‘OLYMPION’, General Clinic of Patra, Patra, Greece, 4Rheumatology Department, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK, Coventry, United Kingdom, 5University Hospital of Orléans, Orleans, France, 6Rheumatologische Schwerpunktpraxis, Berlin, Germany, 7Clinic of Rheumatology, University Hospital St. Ivan Rilski, Sofia, Bulgaria, 8Novartis Pharma AG, Basel, Switzerland, 9Novartis Farmaceutica, Madrid, Spain, 10Novartis Pharmaceuticals Corporation, East Hanover, NJ, 11Novartis Pharmaceuticals Corporation, Hanover, NJ, 12Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, United Kingdom

    Background/Purpose: Patients with psoriasis (PsO), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA) are at increased risk of major adverse cardiovascular events (MACE) due to systemic…
  • Abstract Number: 0223 • ACR Convergence 2025

    Timely Dermatologic Diagnosis and Management Changes in Systemic Collagen Vascular Diseases: Experiences from the Rheumatology-Dermatology Combined Clinic

    Gopisree Peringeth1, Benedict Wu1, Shudan Wang2, Beth McLellan3, Clement Tagoe4 and Jeanie Lee1, 1Albert Einstein College of Medicine - Montefiore Medical Center, Bronx, NY, 2Montefiore Medical Center, Bronx, NY, 3Albert Einstein College of Medicine - Montefiore Medical Center, Bronx, 4Albert Einstein College of Medicine, FRESH MEADOWS, NY

    Background/Purpose: Collagen vascular diseases (CVD) often present with skin manifestations, but it is not always clear whether these changes are directly related to the underlying…
  • Abstract Number: 1448 • ACR Convergence 2025

    Influence of Sex on the Therapeutic Persistence of Guselkumab in Psoriatic Disease: a Retrospective National Cohort Study

    Laure Gossec1, Pascal Claudepierre2, Arnaud Constantin3, Denis Jullien4, Samira Chaalal5, Julie Baraut5, Laure Cipiere5, Laurène Gautier6, Pierre Lemire7 and Thierry Passeron8, 1Sorbonne Universite and Pitie-Salpetriere Hospital, Paris, France, 2Department of Rheumatology, CHU Henri Mondor, AP-HP, Créteil, France, Creteil, France, 3Department of Rheumatology, Toulouse University Hospital, Toulouse University and INSERM U1291, France, Toulouse, France, 4Hospices Civils de Lyon, Hôpital E. Herriot Department of Dermatologie, Lyon F-69003 ; CIRI, Centre International de Recherche en Infectiologie, Team EIA : Epidermal immunity & Allergy, INSERM, U1111; Univ Lyon; Université de Lyon 1; Ecole Normale Supérieure de Lyon; CNRS, UMR 5308, Lyon, France., Lyon, France, 5Johnson & Johnson, Issy les moulineaux, France, 6Johnson & Johson, Issy les Moulineaux, France, 7IQVIA, Real World Solutions, Paris, France, Paris, France, 8Johnson & Johnson, Nice, France

    Background/Purpose: Psoriatic disease, including psoriasis (Pso) and psoriatic arthritis (PsA), seems to affect male and female patients differently in clinical presentation, disease progression and advanced…
  • Abstract Number: 1166 • ACR Convergence 2025

    Biomarkers Associated with Left Atrial Structure and Function in Individuals with Psoriasis

    Julie Borchsenius1, Maria Dons2, Morten Sengeløv3, Flemming Olsen4, Caroline Espersen4, Kristoffer Skaarup3, Mats Lassen4, Niklas Johansen4, Filip Davidovski3, Manan Pareek4, Brittany Weber5, Claus Zachariae6, Lone Skov6 and Tor Biering-Sørensen3, 1CTCPR / Center for translational cardiology and pragmatic research trials, Charlottenlund, Denmark, 2Copenhagen University Hospital Gentofte, Copenhagen, Hovedstaden, Denmark, 3Center for Translational Cardiology and Pragmatic Randomized Trials, Dep. of Cardiology, Copenhagen University Hospital - Gentofte, Copenhagen, Hovedstaden, Denmark, 4CTCPR / Center for translational cardiology and pragmatic research trials, Copenhagen, Denmark, 5Brigham and Women's Hospital, DEDHAM, MA, 6Dep. of Dermatology and Allergy, Copenhagen University Hospital – Herlev & Gentofte, Copenhagen, Hovedstaden, Denmark

    Background/Purpose: Individuals with psoriasis are at increased risk of developing heart disease. Echocardiographic parameters of impaired left atrial (LA) strain (Peak atrial contraction and longitudinal…
  • Abstract Number: 1152 • ACR Convergence 2025

    Cutaneous Panniculitis in Rheumatology: A Descriptive Cohort Study from a Multidisciplinary Experience

    Claudia Campos-Fabre1, Carlota Ureta-Moneva1, Elena Sendagorta1, Jose Rodríguez-Gago1, Maria José Beato1, Agustin Remesal2, Rosa Alcobendas1, Clara Udaondo1, Gema Bonilla3, Laura Nuño4, Irene Monjo Henry2, Carolina Tornero5 and Chamaida Plasencia-Rodríguez2, 1La Paz University Hospital, Madrid, Spain, 2Hospital Universitario La Paz, Madrid, Spain, 3Hospital Universitario La Paz, Rheumatology, Madrid, Madrid, Spain, 4Hospital Universitario Puerta de Hierro, Madrid, Spain, 5Hospital La Paz, Madrid, Spain

    Background/Purpose: Panniculitis refers to inflammatory disorders of subcutaneous fat that pose diagnostic challenges due to nonspecific clinical features and overlapping histopathological patterns. Although it can…
  • Abstract Number: 0998 • ACR Convergence 2025

    Preclinical Characterization of a Novel Bi-specific Antibody Targeting IL-23p19 and IL-36R for The Treatment of Autoimmune Diseases

    qianqian yin1, changqing run1, kaili liu1, xueqin cui1, fanpeng Meng1, yanru fan1, yifei yang1, wei ye1, Lu Su2, yuan lin1 and cheng liao1, 1Jiangsu Hengrui Pharmaceuticals Co., Ltd, Shanghai, China (People's Republic), 2Jiangsu Hengrui Pharmaceuticals, Shanghai, Shanghai, China

    Background/Purpose: IL-23 is a pivotal cytokine driving IL-17-mediated inflammation, and its inhibition has shown efficacy in Th17-associated autoimmune diseases. However, patient heterogeneity and compensatory pathways…
  • Abstract Number: 2699 • ACR Convergence 2025

    Cutaneous IgA Vasculitis: Emulation of a Target Trial from a European Multicentric Retrospective Study

    Elena Biancamaria Mariotti1, Boris Sorin2, William Lutz3, Chloé Grolleau3, Thomas Bettuzzi4, Caterina Ricordi5, Santos Castañeda6, Luisa Herda7, Cord Sunderkotter7, Rodérau Outh8, Romain Paule9, Alexandra Audemard-Verger10, Marzia Caproni11, Angelo Valerio Marzano12, Pietro Quaglino13, Laura Atzori14, Julien Campagne15, Mehemt Erkan16, Nabil Belfeki17, Marijan Frkovic18, Nicolas Dupin19, Raphael Porcher20, Marie Jachiet21 and Benjamin Terrier19, 1University of Florence, Azienda USL Toscana Centro, Department of Dermatology, Florence, Firenze, Italy, 2Assistance Publique Hôpitaux de Paris, Paris, France, 3University Paris Cité, Hospital Saint Louis, Dermatology department, Paris, Paris, France, 4Université Paris Est Créteil Val de Marne, Hôpital Henri-Mondor (APHP), Service de dermatologie, EpiDermE, Paris, France, 5AUSL-IRCCS Reggio Emilia, Parma, Italy, 6Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, 7Department of Dermatology and Venereology, Martin Luther University Halle-Wittenberg, Halle (Saale), Halle, Germany, 8Department of Internal Medicine, Centre Hospitalier de Perpignan, Perpignan, France., Clermont-Ferrand, France, 9Hospital Foch, Service de medicine interne, Suresnes, Paris, Suresnes, France, 10Department of Internal Medicine, Tours University Hospital, Tours, France., Tours, France, 11University of Florence, Azienda USL Toscana Centro, Department of Dermatology, Florence, Florence, Italy, 12Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Milan, Italy, 13University of Turin, Department of Medical Sciences, Section of Dermatology, Turin, Torino, Italy, 14Dermatology Clinic, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Cagliari, Italy, 15Hospital Robert Schuman, Metz, France, 16Hacettepe University Faculty of Medicine Department of Pediatric Rheumatology Ankara, Türkiye, Ankara, Turkey, 17Head of the Internal Medicine and Clinical Immunology Department South Île de France Health Hospital Group, Melun Center, Melun, France, 18Division for clinical immunology and rheumatology, Department of pediatrics UHC Zagreb / School of Medicine Zagreb Croatia, Zagabria, Croatia, 19Cochin Hospital, Paris, France, 20Université Paris Cité and Université Sorbonne Paris Nord, INSERM, INRAE, Center for Research in Epidemiology and StatisticS (CRESS), Paris, France, Paris, France, 21University Paris Cité, Hôpital Saint-Louis, Dermatology department, Paris, Paris, France

    Background/Purpose: Immunoglobulin A vasculitis (IgAV) is a small vessel vasculitis marked by IgA, deposition, palpable purpura with lower body predilection and variable joints, kidney and…
  • Abstract Number: 0926 • ACR Convergence 2025

    Discovery and Characterization of SIM0711: a Potent and Selective IRAK4 PROTAC with Improved Efficacy and Safety

    Minyun Zhou1, Peng Gu2, Mengyu Wang3, Yuxi Yan2, Li Sun3, Yiling Chen3, Xin Wang3, Feng Tang1, Shunwei Zhu2 and Xiaofeng Zhao4, 1State Key Laboratory of Neurology and Oncology Drug Development, Simcere Pharmaceutical group, Nanjing, 2State Key Laboratory of Neurology and Oncology Drug Development, Simcere Pharmaceutical Group, Shanghai, China (People's Republic), 3State Key Laboratory of Neurology and Oncology Drug Development, Simcere Pharmaceutical Group, Nanjing, China (People's Republic), 4State Key Laboratory of Neurology and oncolog Drug Development, Simcere Pharmaceutical Group, Nanjing, China (People's Republic)

    Background/Purpose: IRAK4 plays a pivotal role in the innate immune response by acting downstream of Toll-like receptors (TLRs) and the interleukin-1 receptor (IL-1R), with both…
  • Abstract Number: 0930 • ACR Convergence 2024

    The Common Form of the Inflammatory Skin Disease Hidradenitis Suppurativa Is Associated with Low Nicastrin Expression in Dermal Fibroblasts

    Kaitlin Williams, Beita Badiei, Hana Minsky and Luis Garza, Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition characterized by painful nodules and abscesses in intertriginous areas. Despite its increasing prevalence, the etiology…
  • Abstract Number: 0988 • ACR Convergence 2024

    Antinuclear Antibody Positivity and Its Diagnostic Implications for Rheumatic Diseases in Dermatology Patients: A Comprehensive Single Center Analysis

    Yunjung Choi1, Myeung-Su Lee2 and Wan-Hee Yoo3, 1Jeonbuk National University Medical School, Deokjin-gu, Jeollabuk-do, Republic of Korea, 2Wonkwang University Hospital, Iksan, South Korea, 3CHONBUK NATIONAL UNIVERSITY HOSPITAL, JEONJU, Republic of Korea

    Background/Purpose: Cutaneous manifestations are common in rheumatic diseases and can be early indicators. This study investigates the prevalence of rheumatic diseases diagnosed through ANA (Antinuclear…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 8
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology